Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222312 | 1.00 | MAPT (0.52) | MAPTSMN1; SMN2RAB9AATMALOX5 | |
| SCHEMBL29643038 | 1.00 | MAPT (0.52) | MAPTSMN1; SMN2RAB9AATMALOX5 | |
| SCHEMBL15423692 | 0.91 | MAPT (0.49) | MAPTSMN1; SMN2RAB9AATMALOX5 | |
| SCHEMBL20204190 | 0.90 | CYP2D6 (0.51) | MAPTSMN1; SMN2RAB9AATMALOX5 | |
| SCHEMBL28011815 | 0.89 | MME (0.53) | MAPTSMN1; SMN2RAB9AATMALOX5 | |
| SCHEMBL3060705 | 0.86 | MAPT (0.51) | MAPTSMN1; SMN2RAB9AALOX5NPC1 | |
| SCHEMBL7465229 | 0.86 | LMNA (0.63) | MAPTSMN1; SMN2RAB9AATMNPC1 | |
| SCHEMBL6539801 | 0.86 | LMNA (0.63) | MAPTSMN1; SMN2RAB9AATMNPC1 | |
| SCHEMBL14532784 | 0.86 | LMNA (0.63) | MAPTSMN1; SMN2RAB9AATMNPC1 | |
| SCHEMBL28096705 | 0.85 | MAPT (0.50) | MAPTSMN1; SMN2RAB9AATMALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632908-B1 | SULFONAMIDES AS HIV PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2016-05-25 | — | — | EP | disclosed |
| US-9187415-B2 | Sulfonamides as HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-11-17 | — | — | US | disclosed |
| US-9187415-B2 | Sulfonamides as HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-11-17 | — | — | US | disclosed |
| US-20140018326-A1 | SULFONAMIDES AS HIB PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-01-16 | — | — | US | disclosed |
| US-20140018326-A1 | SULFONAMIDES AS HIB PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-01-16 | — | — | US | disclosed |
| EP-2114158-B1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2012055034-A1 | SULFONAMIDES AS HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2012-05-03 | — | — | WO | disclosed |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018326-A1 | SULFONAMIDES AS HIB PROTEASE INHIBITORS | PRSS1, PRSS3, PRSS2 | MAPT 2270/4885SMN1; SMN2 2665/4885RAB9A 1388/4885 |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | GRIN1, GRIN3B, GABRE | MAPT 482/4885SMN1; SMN2 1637/4885RAB9A 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.